The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
These FAQs address questions related to prescription drug importation, including the current status of importation proposals, details of Florida’s importation program recently authorized by the FDA, and concerns and challenges with this approach.
This poll finds that inflation and health care affordability are the top issues voters want 2024 presidential candidates to discuss, as most rate the economy negatively. Adults worry most about affording unexpected medical bills and health care costs, and the Affordable Care Act remains popular despite partisan differences when it comes to its future.
Half of adults say they have difficulty affording monthly bills or are just able to afford household expenses without having money left over. These groups overwhelmingly rate the economy negatively and are more likely to want 2024 presidential candidates to discuss economic issues.
At a time when kitchen table economic problems are on voters’ minds, unexpected medical bills and health care costs top the public’s list of financial concerns, and voters who are struggling to pay their monthly bills are the most eager to hear the presidential candidates talk about economic and health care issues, the latest KFF…
This post was updated to clarify that less than 10% of the nation's total health spending is spent on retail prescription drugs and does not include spending on drugs administrated by physicians or in hospitals.Prescription drug costs are a top concern for the American public.
Under the Inflation Reduction Act, the federal government for the first time will negotiate directly with drug companies to determine the prices that Medicare will pay for certain high expenditure drugs covered under Medicare Part D (starting in 2026) and Part B (starting in 2028).
While issues of health care costs and affordability may not be at the forefront of this year’s election issues, they remain a major concern among the public.
This policy watch explains the Medicaid prescription drug rebate cap, examines how many drugs might be impacted, and explores the implications of recent manufacturer responses for Medicaid programs and enrollees.
A new KFF policy watch explains some of the hurdles the state of Florida still must clear before it can implement its novel plan to make some prescription drugs more affordable by importing them from Canada.
© 2026 KFF